Pay in 4 interest-free payments of $7.37 Learn more
Ships within 48 hours · Estimated delivery Aug 18 - Aug 23
To assess the association of semaglutide with incident AUD, the study population included 598,803 patients with T2DM who had active medical encounters for T2DM during 12/20175/2021, were for the first time prescribed semaglutide or non-GLP1-1RA anti-diabetes medications (new-user design) during 12/20175/2021(index event), had no diagnosis of AUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
The weight loss effects of semaglutide appear to be dose-dependent higher doses have been associated with higher average body weight loss over time
Designation: RUO Research Use Only
Fifth, we did not estimate lifetime benefits and costs of these medications, which has implications for the interpretation of the age-stratified results
Contraception , 78(5), 373-385
US$ 27.13
US$ 25.97
US$ 21.67
